A Phase 1 interventional study of Darunavir and Ritonavir in HIV Infections, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-31.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing darunavir in HIV Infections — 2 open to participants now, 3 under way, 2 of them phase 3. Darunavir · HIV Infections.
Among the 38 studies testing darunavir in HIV Infections, this one is the 34th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 1, and was the 28th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →2 of the 38 studies testing darunavir in HIV Infections are open now, in 1 country. Recruiting first, the newest first:
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+ · Men only
University College, London
Ages 4 wk–14 yrs
By country, each count listing its studies:
Darunavir: first FDA approval 2006 (PREZISTA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 14 · Phase 4 11
First in 2001; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 90 across the 38 interventional studies. Of the 33 that completed or were terminated, 13 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 38 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
67 studies in HIV Infections by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 62 finished, 24 (39%) have results posted.
Among the 67 studies in HIV Infections by Boehringer Ingelheim, this one is the 40th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2011, is one of 12 in phase 1, and was the 48th registered.
Boehringer Ingelheim’s HIV Infections studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 38 studies testing darunavir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 67 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the current study is to investigate the effect of multiple oral daily doses of BI 201335 on the steady-state pharmacokinetics of darunavir co-administered with ritonavir.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
capsule for oral administration
Drug: BI 201335
tablet for oral administration
Drug: Darunavir
tablet for oral administration
Drug: Ritonavir
AUCτ,ss of Darunavir
area under the concentration-time curve of the analyte in plasma at steadystate over a uniform dosing interval τ of darunavir. The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities
Time frame: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)
Cτ,ss of Darunavir
concentration of the analyte in plasma at steady-state after a uniform dosing interval τ=24h of darunavir
Time frame: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)
Cmax,ss of Darunavir
maximum measured concentration of the analyte in plasma at steady-state
Time frame: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 h after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)
Tmax,ss of Darunavir
time from last dosing to maximum concentration of the analyte in plasma at steady state
Time frame: 0:00, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00,12:00 hours (h) after drug administration on day 8 (DRV/r) and day 16 (BI 201335+DRV/r)
| Milestone | All Subjects |
|---|---|
| Started | 14 |
| Completed | 14 |
| Not completed | 0 |
area under the concentration-time curve of the analyte in plasma at steadystate over a uniform dosing interval τ of darunavir. The measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities
| ng*h/mL | Darunavir+Ritonavir | Faldaprevir+Darunavir+Ritonavir |
|---|---|---|
| AUCτ,ss of Darunavir | 57200 ± 29.5 | 66000 ± 39.9 |
concentration of the analyte in plasma at steady-state after a uniform dosing interval τ=24h of darunavir
| ng/mL | Darunavir+Ritonavir | Faldaprevir+Darunavir+Ritonavir |
|---|---|---|
| Cτ,ss of Darunavir | 1330 ± 49.5 | 1170 ± 90.3 |
maximum measured concentration of the analyte in plasma at steady-state
| ng/mL | Darunavir+Ritonavir | Faldaprevir+Darunavir+Ritonavir |
|---|---|---|
| Cmax,ss of Darunavir | 4930 ± 23.9 | 6330 ± 26.5 |
time from last dosing to maximum concentration of the analyte in plasma at steady state
| h | Darunavir+Ritonavir | Faldaprevir+Darunavir+Ritonavir |
|---|---|---|
| Tmax,ss of Darunavir | 1.50 ± 33.9 | 2.01 ± 37.3 |
Collected over Adverse events (AEs) occurring up to 9 days after first drug administration of DRV/r were assigned to the treatment DRV/r and AEs occurring up to 13 days after last drug administration of DRV/r+FDV were assigned to the combined treatment DRV/r+FDV.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Darunavir+Ritonavir | — | 0/14 (0%) | 7/14 (50%) |
| Faldaprevir+Darunavir+Ritonavir | — | 0/14 (0%) | 11/14 (78.6%) |
| Event | Darunavir+Ritonavir | Faldaprevir+Darunavir+Ritonavir |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/14 | 6/14 |
| Abdominal distensionGastrointestinal disorders | 0/14 | 4/14 |
| HeadacheNervous system disorders | 2/14 | 3/14 |
| FatigueGeneral disorders | 3/14 | 0/14 |
| NauseaGastrointestinal disorders | 1/14 | 2/14 |
| Decreased appetiteMetabolism and nutrition disorders | 0/14 | 1/14 |
| InsomniaPsychiatric disorders | 0/14 | 1/14 |
| NervousnessPsychiatric disorders | 0/14 | 1/14 |
| Sleep disorderPsychiatric disorders | 1/14 | 0/14 |
| DizzinessNervous system disorders | 1/14 | 0/14 |
The study was performed as an open-label, multiple-dose, single-group, fixed-sequence study in 14 healthy volunteers.
| Age, Continuous(years) | All Subjects |
|---|---|
| Mean | 40.4 ± 9.9 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 2 |
| Male | 12 |
The record gives a start of Jun 2011 and a primary completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Darunavir · Ritonavir · Faldaprevir